Sareum yesterday announced the initiation of a Phase 1a clinical trial for its lead molecule SDC-1801. The trial has started with patient recruitment in progress at specialist clinical units located in Victoria, Australia. SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis.
The initial Phase 1a trial is designed to investigate the safety and pharmacokinetics of an oral formulation of SDC-1801 in ....
19 May 2023
Hybridan Research: 19/05/2023: Sareum Holdings plc: Commencement of patient recruitment for Phase 1 clinical trial of SDC-1801
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hybridan Research: 19/05/2023: Sareum Holdings plc: Commencement of patient recruitment for Phase 1 clinical trial of SDC-1801
Sareum Holdings plc (SAR:LON) | 30.5 -0.9 (-9.0%) | Mkt Cap: 31.0m
- Published:
19 May 2023 -
Author:
Sacha Morris | Emily Liu -
Pages:
5
Sareum yesterday announced the initiation of a Phase 1a clinical trial for its lead molecule SDC-1801. The trial has started with patient recruitment in progress at specialist clinical units located in Victoria, Australia. SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis.
The initial Phase 1a trial is designed to investigate the safety and pharmacokinetics of an oral formulation of SDC-1801 in ....